IL15 and cancer: For most cancer patients, the intratumoral administration of immunotherapy is not an option; thus, more work is needed to improve the safety and targeting of IL-15 agents; however, this recent approval highlights the transformative potential of IL-15R agonists if they are specifically targeted to the TME.